Leadership

Patricia S. Andrews serves as the Chief Executive Officer and Global Head of Oncology. Prior to joining Sumitomo Dainippon Pharma Oncology (SDP Oncology), Ms. Andrews spent seven years at Boston Biomedical, Inc., one of the predecessor companies, and served as Chief Executive Officer and Chief Operating Officer.

Prior to joining Boston Biomedical, Ms. Andrews served as Executive Vice President and Chief Commercial Officer at Incyte Corporation, a U.S.-based biopharmaceutical company. In this role, she led the transition from a clinical-stage research and development organization to a successful commercial enterprise with the launch of its first-for-the-company, first-in-class, first-in-disease, orphan oncology product. She established the commercial organization and led all functions within sales and marketing. She was also responsible for business development and completed multiple significant product licensing deals for Incyte, including one of the largest licensing deals in biotech in 2009.

Prior to her experience at Incyte, Ms. Andrews spent 17 years at Pfizer Inc., culminating in her role as Vice President and General Manager of the U.S. Oncology Business Unit, at the time a $900 million portfolio of products in colorectal cancer, breast cancer, and renal cell carcinoma. Ms. Andrews is an Executive Officer of Sumitomo Dainippon Pharma Co., Ltd. and serves on the board of GlycoMimetics [Nasdaq: GLYC]. Ms. Andrews received her MBA from the University of Michigan and a BA from Brown University.

David J. Bearss, Ph.D. serves as the Chief Scientific Officer and Global Head of Research. Prior to joining SDP Oncology, Dr. Bearss founded Tolero Pharmaceuticals, Inc., one of the predecessor companies, and served as Chief Executive Officer.

Dr. Bearss has established a consistent and successful track record of drug discovery and development that spanned the last 20 years in both academic and industrial settings. Dr. Bearss is an expert in small-molecule drug development and in the use of genetic model systems in drug discovery. He has deep experience in translational research focused on drug development and the use of genetic and functional markers to predict drug sensitivity. He is also an expert in the development and use of genetically modified animals to model human disease. Dr. Bearss received his Ph.D. in Cell and Structural Biology at the University of Texas Health Sciences Center at San Antonio and was a postdoctoral fellow with Dr. Daniel Von Hoff, a recognized leader in oncology drug development. Dr. Bearss was on the faculty of the University of Arizona from 1999 to 2003, after which he co-founded Montigen Pharmaceuticals, where he served as Chief Scientific Officer until Montigen was acquired by SuperGen in 2006. Dr. Bearss served as Chief Scientific Officer at SuperGen, overseeing early drug discovery and development, and was subsequently co-director of the Center for Investigational Therapeutics at the Huntsman Cancer Institute, where he was an Associate Professor in the Department of Oncological Sciences at the University of Utah. Dr. Bearss was also an Associate Professor of Physiology & Developmental Biology at Brigham Young University. Dr. Bearss has published more than 70 manuscripts and book chapters, is an author on over 150 abstracts presented at international meetings, and has more than 50 patents issued or pending. Dr. Bearss has also won several awards for his scientific and entrepreneurial achievements.

Edgar Braendle, M.D., Ph.D. serves as the Chief Medical Officer and Global Head of Development. Prior to joining SDP Oncology, Dr. Braendle spent three years at Boston Biomedical, Inc., one of the predecessor companies, and served as Executive Vice President, Head of R&D and Chief Medical Officer.

Dr. Braendle has more than 20 years of industry experience leading clinical development and oncology diagnostics and treatments. Prior to joining Boston Biomedical, he served as President and CEO of ARUP Laboratories, a national clinical and anatomic pathology reference laboratory. Previously, he spent more than a decade at Novartis Pharmaceutical Corporation, culminating in his role as Senior Vice President and Global Head of Companion Diagnostics. In this role, Dr. Braendle led the company’s precision medicine approach, delivering all complementary and companion diagnostics for Novartis medicines, and driving exploratory biomarker development. In an earlier position as Vice President, Global Head of Oncology Biologics, he developed Novartis oncology biologics in early to late stages, successfully filing eight investigational new drug applications.

Dr. Braendle received a medical degree and training in hematologic malignancies and solid tumor oncology, pharmacology and urology at the University of Aachen, University of Bonn, and the University of Ulm in Germany.